The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A drug-drug interaction study between the strong CYP3A4 inhibitor ketoconazole (keto) and ixazomib citrate (MLN9708), an investigational, orally active proteasome inhibitor, in patients with advanced solid tumors or lymphoma.
Neeraj Gupta
Employment or Leadership Position - Millennium
Karthik Venkatakrishnan
Employment or Leadership Position - Millennium
Dennis A Noe
Employment or Leadership Position - Millennium
Michael J Hanley
Employment or Leadership Position - Millennium
Jiang Yu
Employment or Leadership Position - Millennium
Alberto Bessudo
No relevant relationships to disclose
Sunil Sharma
Research Funding - Millennium
Robert Matthew Strother
No relevant relationships to disclose
Yaping Shou
Employment or Leadership Position - Millennium
John J. Nemunaitis
No relevant relationships to disclose